Pacira Pharma (PCRX): EXPAREL Sales Are Tracking Below Consensus - Wedbush

September 21, 2016 8:16 AM EDT
Get Alerts PCRX Hot Sheet
Price: $33.35 +0.45%

Rating Summary:
    10 Buy, 6 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade PCRX Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Wedbush analyst, Liana Moussatos, reiterated her Outperform rating on shares of Pacira Pharmaceuticals (NASDAQ: PCRX) while noting that the Symphony Health EXPAREL estimated sales per day in August decreased -12% over July and total August sales tracked about -13.6% below consensus. Symphony Health sales and volume estimates for August were more than $21 million and 66-67 thousand pack units.

Combining July and August estimates, EXPAREL appears to be tracking about -7.6% below consensus. The September SH sales estimate is expected to be released on October 19.

No change to the price target of $109.

For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.

Shares of Pacira Pharmaceuticals closed at $40.37 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Liana Moussatos

Add Your Comment